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OBJECTIVE: This study aimed to identify novel PITX2c mutations responsible for idiopathic atrial fibrillation.
METHODS: A cohort of 210 unrelated patients with idiopathic atrial fibrillation and 200 unrelated, ethnically
matched healthy individuals used as controls were recruited. The whole coding exons and splice junctions of
the PITX2c gene, which encodes a paired-like homeobox transcription factor required for normal cardiovascular
morphogenesis, were sequenced in 210 patients and 200 control subjects. The causative potentials of the
identified mutations were automatically predicted by MutationTaster and PolyPhen-2. The functional
characteristics of the PITX2c mutations were explored using a dual-luciferase reporter assay system.
RESULTS: Two novel heterozygous PITX2c mutations (p.Q105L and p.R122C) were identified in 2 of the 210
unrelated patients with idiopathic atrial fibrillation. These missense mutations were absent in the 400 control
chromosomes and were both predicted to be pathogenic. Multiple alignments of PITX2c protein sequences
across various species showed that the altered amino acids were highly evolutionarily conserved. A functional
analysis demonstrated that the mutant PITX2c proteins were both associated with significantly reduced
transcriptional activity compared with their wild-type counterparts.
CONCLUSION: The findings of this study associate PITX2c loss-of-function mutations with atrial fibrillation,
supporting the hypothesis that dysfunctional PITX2c confers enhanced susceptibility to atrial fibrillation and
suggesting potential implications for early prophylaxis and allele-specific therapy for this common arrhythmia.
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& INTRODUCTION
Atrial fibrillation (AF), a supraventricular tachycardia
characterized by rapid and chaotic atrial electrical activity
with subsequent deterioration of atrial mechanical function,
is the most prevalent form of sustained cardiac arrhythmia
in humans worldwide and is responsible for approximately
one-third of all hospital admissions with miscellaneous
heart rhythm disturbances (1). The prevalence of AF is
approximately 1% in the general population and increases
strikingly with advanced age, increasing from ,1% in
individuals younger than 60 years to approximately 10%
in subjects older than 80 years (1). According to the
Framingham Heart Study, the lifetime risk for developing
AF is approximately 25% for people older than 40 years (2).
The prevalence of AF in the United States is currently
estimated at 2.3 million and is projected to exceed 10 million
by 2050 (3). This common arrhythmia significantly con-
tributes to a degraded quality of life, reduced exercise
capacity, cognitive impairment or dementia, tachycardio-
myopathy, thromboembolism, congestive heart failure,
and even death (1,4,5). The mortality of patients with AF
is approximately twice that of age- and gender-matched
patients with normal sinus rhythms, independent of pre-
existing cardiovascular conditions (6). AF patients have a
2- to 7-fold increased risk for ischemic stroke compared with
individuals without AF, and 15%–20% of all strokes are
ascribed to AF (7). Note that the risk of thromboembolism
attributable to AF also increases markedly with increased
age, ranging from 1.5% among patients aged 50–59 years to
23.5% among patients aged 80–89 years (7). Consequently,
AF imposes a substantial economic burden on health care
systems because of its increased morbidity- and mortality-
associated therapeutic interventions. This socioeconomic
burden is anticipated to continually increase in the future as
life expectancies increase (8). Despite its high prevalence
and important clinical significance, the molecular basis of
AF remains poorly understood.
Frequently, AF is associated with diverse structural
heart diseases or systemic disorders, such as ischemic heart
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disease, valvular heart disease, congenital heart disease,
pulmonary heart disease, cardiomyopathy, cardiothoracic
surgery, congestive heart failure, essential hypertension,
and hyperthyroidism (1,9). Other risk factors for AF include
aging, obesity, sleep apnea, cigarette smoking, excessive
alcohol consumption, and exposure to drugs or toxicants
(1,10). However, in 12%–30% of all AF patients and 20%–
45% of younger AF patients, AF occurs alone in the absence
of the above-mentioned underlying diseases or precipitating
factors; this condition is defined as idiopathic or lone AF
and termed familial AF, as at least 15% of patients have
positive family histories of AF (1,11). A growing number
of epidemiological studies have demonstrated the familial
aggregation of AF and the enhanced susceptibility to AF in
the close relatives of AF patients, indicating that genetic risk
factors play key roles in the pathogenesis of AF in a subset
of patients (12). A whole-genome scan with polymorphic
microsatellite markers and linkage analysis mapped the
AF susceptibility loci on human chromosomes 10q22, 6q14-
16, 11p15.5, 5p15, 10p11-q21, and 5p13, for which the AF-
causing mutations in 2 genes, KCNQ1 on chromosome
11p15.5 and NUP155 on chromosome 5p13, were identified
and functionally characterized (13). Analyses of the candi-
date genes revealed a long list of AF-associated genes,
including KCNE2, KCNH2, KCNJ2, KCNA5, SCN5A,
ANP, GJA5, GATA4, GATA5, GATA6, and NKX2-5 (13-
21). Nevertheless, AF is genetically heterogeneous, and the
genetic defects underlying AF in an overwhelming majority
of patients remain to be identified.
Recently, a genome-wide association study identified 2
sequence variants (rs2200733 and rs10033464) on chromo-
some 4q25 that were strongly associated with an enhanced
vulnerability for AF (22). This association was subsequently
replicated in a study of 4 large populations with ambulatory
AF (23) and was also reported for post-cardiac surgery AF
in a setting thought to be related to inflammation (24). More-
over, the 2 sequence variants were observed to increase the
risk for both the early and late recurrences of AF after
catheter ablation (25) and acted as genetic modifiers of rare
ion channel mutations associated with familial AF (26). The
PITX2 gene is closest to these sequence variants; it a member
of the pituitary homeobox (PITX) family of transcription
factors, which play a pivotal role in embryonic morphogen-
esis. PITX2c is the predominant isoform that is expressed
in embryonic and adult hearts (27). Emerging evidence
underlines the essential role of PITX2c in the embryonic
development of the left atrium, cardiac conduction system,
and pulmonary venous myocardium, a major source of
ectopic activity that is implicated in initiating and main-
taining AF (28). The abnormal expression of PITX2c has
been associated with an increased predisposition to AF (29-
31). These findings justify screening for PITX2c as a prime
candidate gene for idiopathic AF.
& MATERIALS AND METHODS
Ethics statement
This study was performed in compliance with the ethical
principles of the revised Declaration of Helsinki (Somerset
West, Republic of South Africa, 1996). The research protocol
was reviewed and approved by the local institutional ethics
committee, and written informed consent was obtained
from all participants prior to the study.
Study subjects
A cohort of 210 unrelated patients with idiopathic AF was
recruited from the Han Chinese population. Patients with
enlarged left atriums ($40 mm in left atrial diameter) were
excluded. A total of 200 ethnically matched, unrelated
healthy individuals were enrolled as the controls. Peripheral
venous blood samples were prepared, and clinical data,
including medical records, electrocardiogram, and echo-
cardiography reports, were collected. The study subjects
were clinically classified using a consistently applied set of
definitions (11,18). Briefly, the AF diagnosis was made using
a standard 12-lead electrocardiogram demonstrating no P
waves and irregular R-R intervals, regardless of the clinical
symptoms. Idiopathic AF was defined as AF occurring in
individuals without other cardiac or systemic diseases using
a physical examination, electrocardiogram, transthoracic
echocardiogram, or extensive laboratory tests. Subjects were
classified as ‘healthy’ if they were asymptomatic and had
normal electrocardiograms. In addition, paroxysmal AF was
defined as AF lasting more than 30 seconds that terminated
spontaneously. Persistent AF was defined as AF lasting
more than 7 days and requiring either pharmacologic
therapy or electrical cardioversion for termination. AF that
was refractory to cardioversion or that was allowed to
continue was classified as long-lasting persistent AF.
Genetic scan
Genomic DNA was extracted from the peripheral venous
blood lymphocytes of all participants with a Wizard
Genomic DNA Purification Kit (Promega, Madison, WI,
USA). The whole coding region and splice junction sites
of PITX2c was sequenced in 210 unrelated patients with
idiopathic AF, and the genotyping PITX2c in the 200 control
individuals was performed subsequently to identify the
presence of mutations in the patients. The referential
genomic DNA sequence of PITX2c was derived from
the GenBank (accession No. NC_000004), which is at the
National Center for Biotechnical Information (NCBI, http://
www.ncbi.nlm.nih.gov/). The primer pairs used to amplify
the coding exons and exon-intron boundaries of PITX2c
by polymerase chain reaction (PCR) were designed with
the help of the online Primer 3 program (http://frodo.wi.
mit.edu), as shown in Table 1. PCR was performed using
HotStar Taq DNA Polymerase (Qiagen, Hilden, Germany)
on a Veriti Thermal Cycler (Applied Biosystems, Foster
City, CA, USA) under standard conditions and concentra-
tions of reagents. Amplified products were analyzed on 1%
agarose gels stained with ethidium bromide and purified
with QIAquick Gel Extraction Kit (Qiagen). Both strands of
each amplicon were sequenced with a BigDyeH Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems) under an
ABI PRISM 3130 XL DNA Analyzer (Applied Biosystems).
The sequencing primers were the same as those pre-
viously designed for specific region amplification. The
DNA sequences were analyzed with the DNA Sequencing
Analysis Software v5.1 (Applied Biosystems). The variant
was validated by re-sequencing an independent PCR-
generated amplicon from the subject and meeting the
quality control thresholds with a call rate.99%. In addition,
for an identified sequence variant, the Exome Variant Server
(EVS; http://evs.gs.washington.edu/EVS) and NCBI’s single
nucleotide polymorphism (SNP; http://www.ncbi.nlm.nih.
gov/SNP) online databases were searched to confirm its
novelty.
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Alignment of multiple PITX2c protein sequences
Multiple PITX2c protein sequences across various species
were aligned using the online program MUSCLE, version
3.6 (http://www.ncbi.nlm.nih.gov/).
Prediction of the disease-causing potential of a
PITX2c sequence variation
The disease-causing potential of a PITX2c sequence
variation was predicted using MutationTaster (an online
program at http://www.mutationtaster.org), which auto-
matically provides a probability for the variation to be either
a pathogenic mutation or a benign polymorphism. Note
that the p-value used here is the probability of the correct
prediction rather than the probability of error, as used in
t-test statistics (i.e., a value close to 1 indicates a high
accuracy of the prediction). Another online program,
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2), was
also used to evaluate the mutational pathogenicity.
Expression plasmids and site-directed mutagenesis
The recombinant expression plasmid PITX2c-pcDNA4,
which was constructed by M. Hermina Strungaru et al. (32),
was a gift from Prof. Georges Christe´, Physiopathologie des
Troubles du Rythme Cardiaque, Faculte´ de Pharmacie de
Lyon, Universite´ Lyon 1, Lyon, France. The atrial natriuretic
factor (ANF)-luciferase reporter plasmid, which contains the
2600-bp 5’-flanking region of the ANF gene, namely ANF
(-2600)-Luc, was kindly provided by Dr. Ichiro Shiojima,
from the Department of Cardiovascular Science and
Medicine, Chiba University Graduate School of Medicine,
Chuo-ku, Chiba, Japan. Each of the identified mutations was
introduced into the wild-type PITX2c using a QuickChange
II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA, USA) with a complementary pair of primers. The
mutants were sequenced to confirm the desired mutations
and to exclude any other sequence variations.
Luciferase reporter gene assay
Chinese hamster ovary (CHO) cells were cultured in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum, 100 units/ml penicillin, and 100 mg/ml
streptomycin. CHO cells were grown 24 h prior to the
transfection. The ANF(-2600)-Luc reporter construct and
an internal control reporter plasmid pGL4.75 (hRluc/CMV,
Promega) were used in transient transfection assays to
explore the transactivational activity of the PITX2c mutants.
The CHO cells were transfected with 2 mg of wild-type
PITX2c–pcDNA4, mutant PITX2c–pcDNA4 (Q105L or
R122C), or empty vector pcDNA4, 2.0 mg of ANF(-2600)-
Luc reporter construct, and 0.04 mg of pGL4.75 control
reporter vector using Lipofectamine 2000 Transfection
Reagent (Invitrogen, Carlsbad, CA, USA). For the co-
transfection experiments, 1 mg of wild-type PITX2c–
pcDNA4, 1 mg of mutant PITX2c–pcDNA4 (Q105L or
R122C), 2.0 mg of ANF(-2600)-Luc, and 0.04 mg of pGL4.75
were used. The transfected cells were incubated for 24 h, and
then they were lysed and assayed for the reporter activities.
Firefly luciferase and Renilla luciferase activities were mea-
sured with the Dual-Glo luciferase assay system (Promega).
The activity of the ANF promoter was presented as the
fold activation of Firefly luciferase relative to the Renilla
luciferase. A minimum of three independent experiments
were performed for wild-type or mutant PITX2c.
Statistical analysis
The data are expressed as the means¡SD. Continuous
variables were tested for normality of distribution, and
Student9s unpaired t-test was used to compare the numeric
variables between 2 groups. The categorical variables were
compared between 2 groups using Pearson’s chi-squared
test or Fisher9s exact test, as appropriate. A 2-sided p-value
,0.05 was considered statistically significant.
& RESULTS
Clinical characteristics of the study population
A cohort of 210 unrelated patients with idiopathic AF
were enlisted, clinically evaluated, and compared with 200
ethnically matched, unrelated healthy individuals. None of
the participants had the traditional risk factors for AF. There
were no significant differences between the patient and
control groups in the baseline characteristics, including age,
gender, body mass index, blood pressure, fasting blood
glucose, serum lipid, left atrial dimension, left ventricular
ejection fraction, heart rate at rest, and lifestyle (data not
shown). The baseline clinical characteristics of the 210
patients with idiopathic AF are summarized in Table 2.
PITX2c mutations
Two heterozygous missense mutations in PITX2c were
identified in 2 of the 210 unrelated patients with idiopathic
AF. The total population prevalence of PITX2c mutations
based on the patient cohort was approximately 0.95%.
Specifically, a substitution of thymine (T) for adenine (A)
in the second nucleotide of codon 105 (c.314A.T), which
predicted the transition of glutamine (Q) into leucine (L) at
amino acid 105 (p.Q105L), was identified in a 52-year-old
female patient who was initially diagnosed with AF at the
age of 35 years. A change of cytosine (C) into thymine (T) in
the first nucleotide of codon 122 (c.364C.T), corresponding
to the transversion of arginine (R) into cysteine (C) at amino
acid 122 (p.R122C), was found in a 48-year-old male patient
who was first diagnosed with AF at the age of 21 years. The
2 mutation carriers had no apparent malformations in the
eyes, teeth, umbilicus, or heart and had no positive family
history. No relatives from these 2 mutation carriers were
available for PITX2c genotyping. The sequence chromato-
grams showing the detected heterozygous PITX2c muta-
tions of c.314A.T and c.364C.T in contrast to their control
sequences are shown in Figures 1A and 1B, respectively.
A schematic diagram of PITX2c showing the structural
domains and the locations of the identified mutations is
Table 1 - Primers to amplify the coding exons and exon-intron boundaries of PITX2c.
Exon Forward primer (59 to 39) Reverse primer (59 to 39) Size (bp)
1 CAG,CTT,GGC,TTG,AGA,ACT,CG TGA,CTT,CCT,TGG,GGC,GAG,AG 442
2 CAG,CTC,TTC,CAC,GGC,TTC,TG GCT,GCC,TTC,CAC,ATT,CTC,TC 387
3 AAT,CTG,CAC,TGT,GGC,ATC,TG AGT,CTT,TCA,AGG,GCG,GAG,TT 677
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presented in Figure 2 (33,34). These missense mutations
were neither observed in the control population nor
reported in the EVS and NCBI SNP databases.
Alignments of multiple PITX2c protein sequences
across species
The alignment of PITX2c protein sequences across 11
species ranging from humans to mammals and insects
showed that the altered amino acid residues were com-
pletely (for p.R122) or highly (for p.Q105) evolutionarily
conserved among PITX2c orthologs, which suggested
that these particular arginine and glutamine residues in
the homeodomain of PITX2c are functionally important
(Figure 3).
Disease-causing potential of the PITX2c variations
The PITX2c sequence variations of c.314A.T and
c.364C.T were both automatically predicted by Mutation-
Taster to be disease-causing mutations with the same
p-value of 1.0. No SNP in the altered regions was found in
the MutationTaster database. The 2 PITX2c sequence
variations were also predicted by PolyPhen-2 to most likely
be damaging, with scores of 0.999 for c.314A.T (sensitivity
0.14; specificity 0.99) and 1.000 for c.364C.T (sensitivity
0.00, specificity 1.00).
Transcriptional activity of the PITX2c mutants
The same amounts of wild-type (2 mg), Q105L-mutant
(2 mg), and R122C-mutant PITX2c (2 mg) activated the
ANF promoter by ,9-fold, ,3-fold, and ,2-fold increases,
respectively, compared with the empty plasmid. When the
same amount of wild-type PITX2c (1 mg) was cotransfected
with Q105L-mutant PITX2c (1 mg) or R122C-mutant PITX2c
(1 mg), the induced activation of the ANF promoter was a
,5-fold increase, compared with the empty plasmid
(Figure 4).
& DISCUSSION
In the present study, 2 novel heterozygous PITX2c
mutations, p.Q105L and p.R122C, were identified in 2
unrelated patients with idiopathic AF; these mutations
were absent in the 400 reference chromosomes and were
both predicted to be pathogenic by MutationTaster and
PolyPhen-2. A cross-species alignment of PITX2c protein
sequences showed that the altered amino acids are highly
evolutionarily conserved. The functional analysis demon-
strated that the mutant PITX2c proteins are associated with
significantly decreased transcriptional activity. Therefore, it
is likely that having functionally impaired PITX2c predis-
poses a patient to AF.
PITX2 is expressed as several protein isoforms, which are
generated by differential mRNA splicing and alternative
translation initiation sites. In the human and the mouse,
the transcriptionally functional isoforms are PITX2-a, -b,
and -c, which share an identical homeodomain and carboxyl
terminus but differ in their amino termini. Humans possess
an additional isoform, the D isoform, which lacks the
amino-terminal domain and most of the homeodomain (31).
PITX2c is the major isoform that is expressed asymme-
trically in the developing and adult heart and plays a crucial
role in normal cardiovascular genesis and maturation
(30,31). The human PITX2c gene maps to chromosome
4q25, which consists of 3 exons coding for a protein of 324
amino acids (35). One of the most important functional
domains of PITX2c is the homeodomain that recognizes
and binds to the specific consensus DNA sequence 59-
TAATCC-39. This homeodomain is essential for DNA
binding, nuclear translocation, and interaction with other
Table 2 - Baseline clinical characteristics of the study subjects.*
Clinical characteristics Patient group (n=210) Control group (n=200)
Male (%) 96 (46) 92 (46)
Age at the initial AF diagnosis (years) 53.2¡8.7 NA
Age at the time of the study (years) 56.7¡10.1 58.3¡9.5
Type of AF at presentation
Paroxysmal AF (%) 147 (70) 0 (0)
Persistent AF (%) 38 (18) 0 (0)
Long-lasting persistent AF (%) 25 (12) 0 (0)
Positive family history of AF (%) 32 (15) 0 (0)
History of cardioversion (%) 178 (85) 0 (0)
Implanted cardiac pacemaker (%) 6 (3) 0 (0)
Resting heart rate (beats per minute) 76.5¡11.8 77.2¡10.5
Systolic blood pressure (mmHg) 130.4¡12.6 131.0¡13.3
Diastolic blood pressure (mmHg) 85.8¡7.3 86.2¡8.1
Body mass index (kg/m2) 22.7¡2.0 23.0¡2.4
Left atrial dimension (mm) 38.2¡3.6 37.5¡3.9
Left ventricular ejection fraction (%) 62.8¡7.2 63.4¡6.7
Fasting blood glucose (mmol/L) 4.5¡0.4 4.6¡0.5
Total cholesterol (mmol/L) 4.2¡0.3 4.1¡0.4
Triglycerides (mmol/L) 1.6¡0.2 1.5¡0.3
Medications
Amiodarone (%) 160 (76) 0 (0)
Warfarin (%) 151 (72) 0 (0)
Digoxin (%) 44 (21) 0 (0)
Beta-blocker (%) 17 (8) 0 (0)
Calcium channel blocker (%) 10 (5) 0 (0)
*There were no significant differences in the baseline characteristics between the patient and control groups.
NA indicates not applicable or not available.
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transcription factors (35). The PITX2c mutations of p.Q105L
and p.R122C, which are identified in the present study,
are both located in this homeodomain; thus, they may be
expected to influence the transcriptional activity of PITX2c
by interfering with its DNA-binding ability.
Previous studies have corroborated that PITX2c is
an upstream regulator of multiple target genes that are
expressed in the heart during embryogenesis, including
the gene that encodes ANF (36). Therefore, the functional
role of a PITX2c mutation can be characterized by an assay
of the transcriptional activity of the ANF promoter in the
cells expressing PITX2c mutants, in contrast to the wild-type
counterpart. In this study, the functional characteristics of
the 2 novel PITX2c mutations identified in the AF patients
Figure 1 - Sequence electropherograms showing the PITX2c mutations in contrast with their corresponding controls. The arrows
indicate the heterozygous nucleotides of A/T (Figure 1A, mutant) or C/T (Figure 1B, mutant) or the homozygous nucleotides of A/A
(Figure 1A, wild-type) or C/C (Figure 1B, wild-type). The rectangle designates the nucleotides comprising a codon of PITX2c.
Figure 2 - A schematic representation of the PITX2c protein structure with the atrial fibrillation-related mutations indicated. The
mutations identified in patients with atrial fibrillation are shown above the structural domains. NH2 means amino-terminus; TAD1,
transcriptional activation domain 1 (amino acids 1–91); HD, homeodomain (amino acids 92–151); NLS, nuclear localization signal
(amino acids 145–161); TID1, transcriptional inhibitory domain 1 (amino acids 162–212); TAD2, transcriptional activation domain 2
(amino acids 213–285); TID2, transcriptional inhibitory domain 2 (amino acids 286–324); and COOH, carboxyl-terminus.
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were delineated by a transcriptional activity analysis, the
results of which showed that both mutations were asso-
ciated with a significantly reduced transcriptional activity
on a downstream gene. This result suggests that the dys-
functional PITX2c resulting from mutations is potentially an
alternative pathological mechanism in AF.
The finding that functionally impaired PITX2c contributes
to AF may be partially attributed to the abnormal deve-
lopment of cardiovascular system, especially pulmonary
venous myocardium (37,38). PITX2c is abundantly ex-
pressed in the atria and pulmonary myocardium, down-
regulating the sinoatrial nodal gene program, for example,
Shox2, HCN4 and Cav3.1, and upregulating a gene program
characteristic of a working myocardium phenotype, for
example, Nkx2.5, Cx40, Cx43, ANP, and Kir2.1 (27,29,31,37).
Therefore, PITX2c loss-of-function mutations presumably
predispose a patient to AF by inducing the identity switch
of the atrial and pulmonary myocardium to a sinoatrial
node–like phenotype, thereby forming an electrophysiolo-
gical substrate that favors AF. Another equally compelling
explanation is that dysfunctional PITX2c may change the
expression profile of ion channels in the atrium, including
an increased expression of the potassium-channel gene
KCNQ1, which alters atrial repolarization, as suggested by
the gene expression analysis and functional studies in
PITX2-deficient mice (29,31,39).
It has been shown that some downstream genes are
transactivated by PITX2c (27), and mutations in multiple
target genes, including Nkx2.5, Cx40, Cx43, and ANP, have
been causally implicated in AF (14,21,40-42). This result
implies that mutated PITX2c may confer vulnerability to AF
by downregulating the expressions of these target genes.
Therefore, additional experiments investigating whether
PITX2c mutations can modify the expression levels of some
Figure 3 - Alignment of the multiple PITX2c protein sequences across species. The altered amino acids of p.Q105 and p.R122 are highly
evolutionarily conserved among the various species.
Figure 4 – The functional defects associated with the PITX2c
mutations. The activation of an atrial natriuretic factor (ANF)
promoter-driven luciferase reporter in the CHO cells by PITX2c
wild-type (WT), Q105L-mutant, or R122C-mutant, alone or in
combination, demonstrated a significantly decreased transacti-
vational activity by the mutant proteins. The experiments were
performed in triplicate, and the means and standard deviations
are shown. ** indicates p,0.001 and * denotes p,0.01, when
compared with the same amount (2 mg) of wild-type PITX2c.
PITX2c mutations in AF
Qiu XB et al.
CLINICS 2014;69(1):15-22
20
of the genes involved in the AF pathogenesis are still
required.
Notably, PITX2 mutations were previously implicated in
type 1 Axenfeld-Rieger syndrome, type 2 iridogoniodysgen-
esis, Peters’ anomaly, ring dermoid of cornea, and con-
genital cardiac malformation (33,43-45). In this study, the
mutations identified in the AF patients were in the home-
odomain shared by PITX2a, PITX2b, and PITX2c, which
implies that mutated PITX2 may also be responsible for AF.
In addition, Yang et al. (46) previously screened 152 index
patients with familial AF who were enlisted from the Han
Chinese population. They identified 2 novel heterozygous
PITX2c mutations, including c.110C.G, corresponding to
p.S37W, and c.840 T.A, which resulted in p.Y280X in 2
of the 152 AF probands, with a mutational prevalence of
approximately 1.32%. The authors’ analysis of the pedigrees
showed that each mutation that co-segregated with AF
was transmitted in an autosomal dominant manner in the
family, with complete penetrance. However, the functional
characteristics of the PITX2 mutations associated with
familial AF remain to be addressed.
In conclusion, this study links PITX2c loss-of-function
mutations to AF for the first time, provides evidence
that functionally impaired PITX2c is associated with an
increased vulnerability to AF, and identifies the potential
implications for early prophylaxis and allele-specific thera-
pies for this common arrhythmia.
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